Chaeseong Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chaeseong Lim has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dokyoung Kim
College of Medicine, Kyung Hee University, Seoul, Republic of Korea
1 shared publication - Hyeoncheol Oh
Department of Occupational and Environmental Medicine, Kosin University Gospel Hospital, Busan, Korea
1 shared publication - Kihun Kim
Department of Occupational and Environmental Medicine Pusan National University Yangsan Hospital Yangsan Republic of Korea
1 shared publication Kunhee Kim
Department of Internal Medicine University of Connecticut School of Medicine Farmington Connecticut USA
1 shared publicationSu‐Yeon Cho
Natural Product Research Center Korea Institute of Science and Technology (KIST) Gangneung Republic of Korea
1 shared publication- Tae-Jin Song
Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- 23 June 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2129-2137
Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis
Objectives/Background: This study aimed to systematically summarize and pool the available evidence on the risk of incident hypertension associated with calcitonin gene‐related peptide (CGRP)–targeted therapies. CGRP‐targeted therapies have emerged as effective preventive treatments for migraine; however, concerns have been raised regarding their potential hypertensive effects. Prior studies have been limited by small sample sizes, inconsistent definitions of hypertension, and incomplete trial inclusion. Methods: We systematically searched MEDLINE, Embase, and ClinicalTrials.gov up to September 25, 2024. We included randomized controlled trials comparing CGRP‐targeted therapies with placebo or another intervention arm in adult patients with migraine. The primary outcome was incident hypertension as defined by each individual study. Two reviewers independently assessed risk of bias using the Cochrane Risk of Bias 2 tool and rated the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. Results: Eight publications or trial reports, comprising 19 underlying randomized controlled trials, were included. The pooled relative risk (RR) for hypertension with CGRP‐targeted therapies versus control was 0.91 (95% confidence interval [CI] 0.58–1.43; I ² = 0.0%), indicating no statistically significant increased risk. The certainty of evidence for this outcome was rated as very low. Erenumab showed no significant increase in risk (RR 0.71, 95% CI 0.30–1.70), whereas galcanezumab also showed no statistically significant association (RR 1.14, 95% CI 0.54–2.39). Conclusion: CGRP‐targeted therapies were not associated with a statistically significant increase in hypertension risk in patients with migraine, particularly among relatively healthy populations enrolled in short‐term randomized controlled trials. However, the certainty of evidence was very low, and possible variation across agents warrants further study. Longer term comparative studies and real‐world observational studies with standardized blood pressure monitoring are needed to confirm these findings and better define hypertension risk in higher risk patient subgroups.
- 23 June 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2129-2137
Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis
Objectives/Background: This study aimed to systematically summarize and pool the available evidence on the risk of incident hypertension associated with calcitonin gene‐related peptide (CGRP)–targeted therapies. CGRP‐targeted therapies have emerged as effective preventive treatments for migraine; however, concerns have been raised regarding their potential hypertensive effects. Prior studies have been limited by small sample sizes, inconsistent definitions of hypertension, and incomplete trial inclusion. Methods: We systematically searched MEDLINE, Embase, and ClinicalTrials.gov up to September 25, 2024. We included randomized controlled trials comparing CGRP‐targeted therapies with placebo or another intervention arm in adult patients with migraine. The primary outcome was incident hypertension as defined by each individual study. Two reviewers independently assessed risk of bias using the Cochrane Risk of Bias 2 tool and rated the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. Results: Eight publications or trial reports, comprising 19 underlying randomized controlled trials, were included. The pooled relative risk (RR) for hypertension with CGRP‐targeted therapies versus control was 0.91 (95% confidence interval [CI] 0.58–1.43; I ² = 0.0%), indicating no statistically significant increased risk. The certainty of evidence for this outcome was rated as very low. Erenumab showed no significant increase in risk (RR 0.71, 95% CI 0.30–1.70), whereas galcanezumab also showed no statistically significant association (RR 1.14, 95% CI 0.54–2.39). Conclusion: CGRP‐targeted therapies were not associated with a statistically significant increase in hypertension risk in patients with migraine, particularly among relatively healthy populations enrolled in short‐term randomized controlled trials. However, the certainty of evidence was very low, and possible variation across agents warrants further study. Longer term comparative studies and real‐world observational studies with standardized blood pressure monitoring are needed to confirm these findings and better define hypertension risk in higher risk patient subgroups.
- Open Access
- 1 January 2023
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 35 (1) , e11
Organic solvent exposure for the chronic kidney disease: updated systematic review with meta-analysis
Lim C, et al. Ann Occup Environ Med. 2023 May;35:e11. https://doi.org/10.35371/aoem.2023.35.e11
- 1 January 2023
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 35 (1) , e11
Open AccessOrganic solvent exposure for the chronic kidney disease: updated systematic review with meta-analysis
Lim C, et al. Ann Occup Environ Med. 2023 May;35:e11. https://doi.org/10.35371/aoem.2023.35.e11